Abstract
Background: The ifosfamide metabolite chloroacetaldehyde had been made responsible for side effects only. We found in previous studies a strong cytotoxicity on human MX-1 tumor cells and xenografts in nude mice. Chloroacetaldehyde is supposed to act via alkylation or by inhibition of mitochondrial oxidative phosphorylation with decrease of ATP. The aim of this study was to further elucidate chloroacetaldehyde’s mode of action. Methods: MX-1 breast carcinoma cells were measured for ATP-content after exposure to chloroacetaldehyde. Further, the effect of chloroacetaldehyde on DNA-synthesis and its potency of causing strand-breaks or cross-links were investigated by bromodeoxyuridine-incorporation, comet-assay and a DNA interstrand cross-linking-assay. Results: Chloroacetaldehyde in high concentrations induces a reduction of ATP-levels when anaerobic glycolysis is blocked by oxamate and reduces the bromodeoxyuridine-incorporation to 46.3% after 4 h when used in IC50 concentrations (7.49 μmol/l). In addition we observed DNA single strand-breaks in MX-1 cells treated with chloroacetaldehyde visible in the Comet assay, but no DNA-cross-linking by comet assay and cross-linking assay. Conclusion: In summary, our results show that chloroacetaldehyde influences the oxidative phosphorylation in mitochondria, however, this is observed only in high concentrations and is not of clinical relevance because the tumor cells regenerate ATP by anaerobic glycolysis. Nevertheless, chloroacetaldehyde causes DNA-strand-breaks and strong inhibition of DNA-synthesis.
Similar content being viewed by others
Abbreviations
- BrdU:
-
Bromodeoxyuridine
- ELISA:
-
Enzyme-linked immuno sorbent assay
- IC50 :
-
Inhibitor concentration 50
- MMS:
-
Methylmethanosulfonate
- MTT:
-
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
- PBS:
-
Phosphate-buffered saline
- Tris:
-
2-Amino-2-(hydroxymethyl)-propan-1,3-diol
References
Kaijser GP, Beijnen JH, Bult A, Underberg WJ (1994) Ifosfamide metabolism and pharmacokinetics (review). Anticancer Res 14:517–531
Wagner T (1994) Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 26:439–456
Furlanut M, Franceschi L (2003) Pharmacology of ifosfamide. Oncology 65:2–6
Huang Z, Roy P, Waxman DJ (2000) Role of human microsomal CYP3A4 and CYP2B6 in catalyzing N-dechlorethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 15:961–972
Nicolao P, Giometto B (2003) Neurological toxicity of ifosfamide. Oncology 65:11–16
Skinner R, Sharkey IM, Pearson AD, Craft AW (1993) Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11:173–190
Aleksa K, Ito S, Koren G (2004) Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. J Lab Clin Med 143:159–162
Brüggemann SK, Schlenke P, Klich S, Deeken M, Peters SO, Wagner T (2002) Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity. Biochem Pharmacol 63:1337–1341
Brüggemann SK, Kisro J, Wagner T (1997) Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res 57:2676–2680
Börner K, Kisro J, Brüggemann SK, Hagenah W, Peters SO, Wagner T (2000) Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Drug Metab Dispos 28:573–576
Chen CS, Lin JT, Goss KA, He YA, Halpert JR, Waxman DJ (2004) Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 65:1278–1285
Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 9:14–23
Brade WP, Herdrich K, Varini M (1985) Ifosfamide–pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1–47
Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R et al (1987) Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311–321
Rodriquez V, McCredie KB, Keating MJ et al (1978) Ifosfamide therapy for hematological malignancies in patients refractory to prior treatment. Cancer Treat Rep 62:493–497
Spengler SJ, Singer B (1988) Formation of interstrand cross-links in chloroacetaldehyde-treated DNA demonstrated by ethidium bromide fluorescence. Cancer Res 48:4804–4806
Kandala JC, Mrema JE, DeAngelo A, Daniel FB, Guntaka RV (1990) 2-Chloroacetaldehyde and 2-chloroacetal are potent inhibitors of DNA synthesis in animal cells. Biochem Biophys Res Commun 167:457–463
Sood C, O’Brien PJ (1993) Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem Pharmacol 46:1621–1626
Dubourg L, Michoudet C, Cochat P, Baverel G (2001) Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 12:1615–1623
Kaijser GP, Beijnen JH, Jeunink EL, Bult A, Keizer HJ, de Kraker J, Underberg WJ (1993) Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma. J Chromatogr 614:253–259
Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36–42
Wiedemann GJ, Siemens HJ, Mentzel M, Biersack A, Wossmann W, Knocks D, Weiss C, Wagner T (1993) Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide. Cancer Res 53:4268–4272
Magaud JP, Sargent I, Mason DY (1988) Detection of human white cell proliferative responses by immunoenzymatic measurement of bromodeoxyuridine uptake. J Immunol Methods 106:95–100
Manfredi G, Yang L, Gajewski CD, Mattiazzi M (2002) Measurements of ATP in mammalian cells. Methods 26:317–326
DeLuca M, McElroy WD (1974) Kinetics of the firefly luciferase catalyzed reactions. Biochemistry 13:921–925
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Singh NP, McCoy MT, Tice RR, Schneider EL(1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184–191
Östling O, Johanson KJ (1984) Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 123:291–298
Penketh PG, Shyam K, Sartorelli AC (1997) Fluorometric assay for the determination of DNA–DNA cross-links utilizing Hoechst 33258 at neutral pH values. Anal Biochem 252:210–213
Singer E, Kuenzle CC, Thoman EP, Ulrich H (1988) DNA fingerprinting: improved DNA extraction from small blood samples. Nucleic Acids Res 16:7738–7739
Liu H, Savaraj N, Priebe W, Lampidis TJ (2002) Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol 64:1745–1751
Wilkinson JH, Walter SJ (1972) Oxamate as a differential inhibitor of lactate dehydrogenase isoenzymes. Enzyme 13:170–176
Matsuno-Yagi A, Hatefi Y (1993) Studies on the mechanism of oxidative phosphorylation. Different effects of F0 inhibitors on unisite and multisite ATP hydrolysis by bovine submitochondrial particles. J Biol Chem 268:1539–1545
Fairbairn DW, Olive PL, O’Neill KL (1995) The comet assay: a comprehensive review. Mutat Res 339:37–59
Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 100:224–229
Küpfer A, Aeschlimann C, Wermuth B, Cerny T (1994) Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 343:763–764
Peters RA (1952) Lethal synthesis. Proc R Soc Lond B Biol Sci 139:143–170
Visarius TM, Stucki JW, Lauterburg BH (1997) Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett 412:157–160
Visarius TM, Stucki JW, Lauterburg BH (1999) Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther 289:820–824
Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA (2004) Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 64:985–993
Simonnet H, Alazard N, Pfeiffer K, Gallou C, Beroud C, Demont J, Bouvier R, Schagger H, Godinot C (2002) Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23:759–768
Kuchenmeister F, Schmezer P, Engelhardt G (1998) Genotoxic bifunctional aldehydes produce specific images in the comet assay. Mutat Res 419:69–78
Brain EG, Yu LJ, Gustafsson K, Drewes P, Waxman DJ (1998) Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br J Cancer 77:1768–1776
Acknowledgements and conflict of interest statement
We thank Heike Bahrs and Monica Vollmert for their skillful technical assistance. None of the authors has a conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brüggemann, S.K., Radike, K., Braasch, K. et al. Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite. Cancer Chemother Pharmacol 57, 349–356 (2006). https://doi.org/10.1007/s00280-005-0061-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0061-0